ABSTRACT. Gaucher disease is the most prevalent lysoGaucher disease is the most prevalent lysosomal storage disease soma1 storage disease. This autosomal recessive disease is (I) and the most frequent genetic disease in the Ashkenazi Jewish caused by the defective activity of the enzyme acid 8-population (2). This autosomal recessive disorder of glycosphinglucosidase and the resultant accumulation of glucosylcer-golipid metabolism results from numerous point mutations at amide primarily within cells of the reticuloendothelial SyS-the locus-encoding acid (3-glucosidase (glucocerebrosidase) (for tern. Because the primary manifestations of Gaucher review, see Ref. 3). The majority of these are missense mutations, disease are due to involvement of mono~yte/macro~hage-which lead to the defective activity of this enzyme (3-5). The derived this disease is be an resultant accumulation of the substrate, glucosylceramide, within candidate for curative intervention via bone marrow trans-m o n o c y t e~m a c r o p~a g e -~e~v e~ cells (~~~ cells) leads to the ~lantation (BMT). A is panic female with subacute neu-visceral manifestations including hepatosplenomegaly, hyperronopathic Gaucher disease and progressing splenism, and skeletal disease (6). Three variants of the disease manifestations underwent BMT at 23 m0 of age using have been delineated based on the absence (type 1, nonneuronher brother as the donor' Cytoge-opathic) or presence (neuronopathic) and severity (type 2, acute; netic analyses demonstrated complete, stable engraftment by 1 mo post-BMT. During the subsequent 24 mo, clinical, type 3 subacute) of primary CNS involvement (6). Because the biochemical, enzymatic, and histologic studies demon-major visceral manifestations of this disease result from the strated nearly complete correction in the viscera. H~~ accumulation of bone marrow-derived tissue-bound macroneuropathic manifestations did not progress. Complete re-phages, Gaucher disease type 1 has been a prime candidate for constitution of enzymatic activity in peripheral blood leu-curative intervention by BMT. In addition, demonstration of the kocytes was achieved by 1 mo. Cytogenetic analyses dem-clinical, biochemical, and histopathologic efficacy of BMT would onstrated complete engraftment by d 79 and nearly corn-provide the basis for ongoing efforts directed toward molecular plete loss of bone marrow Gaucher cells was observed by therapy for this disease. 
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Gaucher disease, and they have stable neurologic status after ri~otent stem cells of selected Gaucher disease patients. BMT. Recently, enzyme augmentation has been clearly demon-(Pediatr Res 31: 503-507,1992) strated to reverse many of the major visceral manifestations of Gaucher disease (10) (11) (12) (13) . Thus, the latter provides an effective, Abbreviations safe (albeit very expensive) treatment, whereas BMT may provide BMT, bone marrow transplantation a more risky curative cellular replacement approach. Lacking an animal model for Gaucher disease, extensive tissue analyses of histologic improvement and enzyme reconstitution 504 TSAI ET AL.
METHODS AND MATERIALS the removed spleen. Mild respiratory distress with intercostal
Materials. The following were from commercial sources: 4-methylumbelliferyl-0-D-glucopyranoside (Genzyme Corp., Boston, MA); 12[N-methyl-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)] dodecanoic acid (Molecular Probes, Junction City, OR); and sodium taurocholate (Calbiochem, San Diego, CA). All other reagents were of the highest available grade. C12-NBD-glucosylceramide (NBD-GC) was prepared and purified as described (14) . Natural glucosylceramide was purified from Gaucher disease splenic extracts and glucosylsphingosine was prepared as described (14) .
Informed consent for BMT as well as tissue samples were obtained according to institutional and National Institutes of Health guidelines. Blood, bone marrow, skin, and liver specimens were obtained by routine procedures.
Methods. Tissue specimens. Mononuclear cells were isolated from peripheral blood by routine methods (14) . The washed pellets were frozen at -20°C until use. Liver specimens were obtained by needle biopsy and quick frozen on dry ice. The specimens were kept frozen at -80°C in tightly sealed tubes until used. Autopsy specimens of brain, liver, lung, kidney, and lymph node were obtained within 7 h of death, quick frozen, and stored at -80°C until assayed. Control normal and Gaucher disease tissues were obtained at autopsy within 2-10 h of death, quick frozen, and stored in tightly sealed tubes at -80°C. Chromosome analyses of bone marrow specimens and phytohemagglutininstimulated peripheral blood cells were conducted according to established protocols (1 5) .
Enzymatic and biochemical analyses. Acid @-glucosidase activities in peripheral blood leukocytes and tissue extracts were determined with the 4-methylumbelliferyl-@-D-glucopyranoside and NBD-GC, substrates as described (4, 14) . The results are reported as the average of triplicate daerminations. Protein concentrations were determined by the Lowry method (16) . Plasma glucosylceramide and globotriaocylceramide concentrations were determined by reversed phase HPLC as described ( 17) . For these determinations, 1-mL aliquots of plasma were frozen in tightly sealed tubes at -80°C. The concentrations are reported as the means of duplicate determinations from two separate assays. Normal values were obtained from pooled lots of outdated pooled human fresh frozen plasma from-at least 10 normal individuals.
Clinical assessments. Serial volumes of the liver were quantitated by established computed tomographic techniques (1 8, 19) . Computed tomography and magnetic resonance imaging scans of the brain were conducted according to routine procedures. '9mTc-sulfur colloid scans were conducted according to our procedure to avoid artifactual diminution in marrow activity in Gaucher disease due to liver, lung, and splenic uptake (20) . Psychomotor evaluations were conducted using the Bayley Scales of Infant Development and the Memll-Palmer Scale of Mental tests in a friendly environment by the same individual who had established rapport with the patient.
CASE REPORT
After an uneventful pregnancy and delivery, this Hispanic female was healthy until 7 mo of age when hepatosplenomegaly was found. Developmental milestones were normal until 7-9 mo of age. Progressive visceral enlargement and growth retardation as well as anemia and thrombocytopenia led to a bone marrow examination at 13 mo of age. Large numbers of Gaucher cells were found. On presentation to the Mount Sinai School of Medicine at 18 mo of age, she was cachectic, the liver was -10 cm below the right costal margin in the mid-clavicular line and the spleen extended across the midline and into the pelvis. Also present was severe failure to thrive (height <3rd percentile, occipital frontal circumference = 50th percentile). Although her weight was at the 50th percentile for age, the spleen constituted about 12% of her body weight as determined from the weight of retractions also was present. The mechanical interference with breathing and severe anemia and thrombocytopenia provided the rationale for a subtotal splenectomy at 18 mo of age. Pneumovax and Haemophilus influenzae B vaccine were administered 2 wk before the removal of about 85% of the splenic mass. However, within 3 mo, rapidly progressive visceral Gaucher disease was evidenced by regrowth of the splenic remnant to 10% of body weight (2 I), pulmonary involvement [Po2 decreased from 97 to 65 mm Hg (1 3 to 9 kPa)], hepatic enlargement (liver extending into the pelvis), and redevelopment of hypersplenism with anemia and thrombocytopenia. These provided the rationale for BMT at 24 mo of age. At that time, she had severe failure to thrive, moderate developmental delay (Table l) , an abnormal EEG with an imtative pattern, and mild cerebral atrophy by computed tomography and magnetic resonance imaging scans. Normal eye movements had been found by neuroophthalmologic exam within 3 mo before BMT. She had a completion splenectomy 1 mo before BMT. One mo before BMT, she developed strabismus due to supranuclear VI cranial nerve palsy. Her normal brother was an HLA homozygous identical match at the A, B, and D loci and was nonreactive by the mixed lymphocyte reaction. He had normal (noncamer) acid @-glucosidase activities in his peripheral blood mononuclear cells and in cultured skin fibroblasts. After anti-thymocyte globulin, busulfan, and cyclophosphamide induction according to standard protocols (22) , she received an infusion of 7.3 x 10' bone marrow mononuclear cellslkg body weight from her donor brother. Methotrexate prophylaxis for graft versus host disease was given on d 1, 3, 7, and 11, and i.v. Ig was administered every 4 wk for six doses. After an uneventful course, she was discharged on d 30. At no time was graft versus host disease detected. She experienced several bouts of bilateral pneumonia during the period from 18 to 21 mo after BMT. Ig levels, lymphocyte number and subsets (23) , mitogen stimulation, and tetanus toxoid levels were normal at the time. She was not reimmunized with Pneumovax and was maintained on daily oral penicillin. She experienced fatal S. pneumoniae sepsis on d 735 post-BMT. Quick frozen as well as fixed tissues were obtained for biochemical and histologic analyses within about 7 h of death.
RESULTS
Clinical evaluations and histologic evaluations. Before BMT, the patient had severe failure to thrive, which was not alleviated by subtotal or total splenectomy. After transplantation, she maintained her weight at about the 30th to 50th percentile and her height increased from less than the 3rd percentile to the 10th percentile by 9 mo post-BMT and to the 50th percentile by 24 mo post-BMT. In addition, the pre-BMT cachexia disappeared by 9-12 mo post-BMT. Serial neuropsychologic testing demonstrated a delay in development pre-BMT with a developmental quotient of 66, which did not change during the post-BMT course (Table 1) . However, by 600 d post-BMT, she was fluently bilingual. Before BMT, her only hard neurologic signs were the strabismus and an irritative pattern on EEG. Post-BMT, the strabismus did not improve, whereas the irritative pattern on EEG disappeared by about 250 d. Mild cerebral atrophy was noted by computed tomography and magnetic resonance imag- Table  2 ). In several representative bone marrow specimens from the ribs, vertebrae, and iliac crests obtained at autopsy (d 735), Gaucher cells were present in small numbers and in clusters and were randomly distributed in the marrow (data not shown). The results of 99mTc-sulfur colloid bone marrow scans were consistent with these histologic findings. Before BMT and after full engraftment at about 80 d post-BMT, 99mTc-sulfur colloid scans revealed decreased central marrow activity with moderate marrow extension and multiple focal defects of the femurs and humeri. On about d 420, a similar scan was completely normal with loss of the focal defects and reestablishment of normal central marrow activity.
Biochemical and enzymatic evaluations. Plasma glucosylceramide levels became consistently normal after about d 150 post-BMT (Fig. 1) . From a pre-BMT mean of 15.8 nmol/mL of plasma, a nearly linear decrease was observed until after d 240, when a plateau in the normal range was maintained. These levels correlated with the disappearance of Gaucher cells from the bone marrow (Table 2) as well as with the loss of Gaucher Kupffer cells from the liver and enzymatic reconstitution in that organ (Table 3) . Serial liver biopsies demonstrated the progressive loss of Gaucher Kupffer cells [from 25% (pre) to <5% (at autopsy)] from the liver. Histologic examination of the liver at autopsy revealed small numbers of Gaucher cells within the portal triads.
These findings were coincident with increasing levels of acid Pglucosidase activity in that organ. Pre-BMT acid P-glucosidase levels were about 11 % of mean normal levels (Table 3) . By d 4 19, this had increased to a constant level of about 43% of mean normal levels.
Acid P-glucosidase levels in other tissues obtained at autopsy from the present patient, normals, and other Gaucher disease patients are shown in Table 4 . In addition to liver, the enzyme levels in lung and lymph nodes were 50-60% of mean normal levels and clearly at much greater levels than in comparable Table 4 . GC and 4MUGlc refer to glucosylceramide and synthetic (3-glucoside substrates, respectively. Some assays to assess GC hydrolytic activity required 10-to 50-fold dilutions to avoid inhibition by stored glucosylceramides. $ The autopsy liver was congested. tissues from other Gaucher disease patients. This correlated well with the histologic resolution of Gaucher disease in the corresponding tissues because Gaucher cells were not found in ileocecal, peritracheal, or retroperitoneal lymph nodes. A few Gaucher cells were found in mesenteric lymph nodes. In lungs, clusters of small numbers of Gaucher cells were found in the alveolar septa and interstitium. No difference in the levels of acid P-glucosidase were found in brain specimens obtained at autopsy from the present patient and comparable specimens from other Gaucher disease patients (Table 4) . DISCUSSION The clinical manifestations of the nonneuronopathic variants (type 1) of Gaucher disease are due almost exclusively to the effects of accumulated glucosylceramides within cells of the reticuloendothelial system (1). It is thought that the vast majority of visceral glucosylceramides which accumulate in Gaucher disease derive from leukocyte membranes, which are presented to tissue-bound macrophages for degradation (24) . As such, complete replacement of monocyte/macrophage precursors with enzymatically corrected progenitors should lead to replacement of the Gaucher cells in reticuloendothelial organs and "cure" this aspect of the visceral manifestations of this disease. The present results indicate that in rapidly progressing Gaucher disease type 3, BMT from a sibling donor with normal enzymatic activity did lead to replacement of Gaucher cells by their normal counterparts in the bone marrow, liver, lung, lymph nodes, and probably, in CNS vascular periadventitial areas. Coincident with correction of the cellular defect, normalization of plasma glucosylceramide levels occurred and enzymatic reconstitution was demonstrated in serial liver biopsies and in other visceral reticuloendothelial organs at autopsy.
Serial histologic examination of bone marrow and liver indicated a differential replacement of Gaucher cells with normal macrophage derivatives in these organs. As determined by iliac crest biopsy, nearly complete clearance of bone marrow Gaucher cells occurred by about 8 mo. This histologic resolution lagged behind the replacement of mitotic bone marrow cells with male donor cells by about 6 mo. Although these studies suggested complete loss of Gaucher cells from the bone marrow, multiple specimens of bone marrow from vertebrae, ribs, and iliac crests at autopsy demonstrated the persistence of scattered rests of Gaucher cells. Similarly, by d 419, the 99mTc-sulfur colloid scan of the bone marrow had normalized with loss of focal uptake defects and reconstitution of central marrow activity. In comparison, the loss of Gaucher cells (Kupffer cells) from the liver was much slower, with a decrease of Gaucher cells estimated per field from 25 to 10% by 4 19 d and with about 5% remaining at 735 d in autopsy specimens. Although serial samples from lymph nodes and lungs were not obtained, scattered Gaucher cells were vresent in these tissues at autovsv 735 d after BMT.
The presence of Gaucher celis the reticuloendothelial organs examined 2 y after successful uncomplicated BMT with persistent complete engraftment indicates the very long life span of the diseased macrophages in this disease. Unlike most other lysosoma1 enzymes, acid P-glucosidase is a membrane-associated enzyme that is not normally secreted in any appreciable amounts (3). Consequently, the loss of Gaucher cells from affected organs can only occur by replacement with normal bone marrowderived cells and turnover of the storage cells in situ. This mechanism is supported by the recent study demonstrating rapid hevatic reaccumulation of Gaucher disease (Ku~ffer cells contaking glucosylceramide) in a patient with ~a u c h e r disease who received a heterologous liver transplant from a donor with normal acid P-glucosidase activity (25) . Thus, bone marrow-derived Kupffer cell precursors with acid P-glucosidase deficiency (i.e. Gaucher cells) repopulated the normal liver, and the hepatocellular acid 6-glucosidase from the normal donor could not crosscorrect the Kupffer cell enzyme defect in this patient.
This inability of normal acid P-glucosidase to cross-correct the enzyme-deficient cells was also reflected by the enzymatic reconstitution in hepatic biopsies. Only about 40-50% of normal hepatic acid P-glucosidase activity was achieved by 4 19 to 735 d after BMT from a donor with normal, not heterozygous, levels of enzyme activity in cultured skin fibroblasts and peripheral blood lymphocytes. If acid P-glucosidase were a secreted lysosoma1 enzyme that could be taken up by hepatocytes, complete reconstitution of hepatic enzyme activity would have been expected. Because Kupffer cells constitute only a part of the total cellular content of hepatic biopsies, only these donor-derived cells in the present patient would contain normal enzyme levels, whereas the hepatocytes would be deficient in acid P-glucosidase activity. Thus, these two populations of cells, enzymatically normal and deficient, would average the total enzyme activity based on their numbers. This rationale might also explain the lower than normal levels of enzyme activity in lymph nodes and in lung, where the enzyme-deficient parenchymal tissues may contribute little to the determined enzyme activity (Table 4) . Similar considerations apply to the selective targeting of exogenous enzyme to reticuloendothelial cells via the mannose receptor (26) (27) (28) on the surface of these cells (10) (11) (12) (13) .
In comparison to the visceral involvement, the basic etiology of the CNS manifestations in the neuronopathic variants (types 2 and 3) is poorly understood, but likely is related to the toxic accumulation of the deacylated glucosylceramide derivative, glucosylsphingosine. However, by analyzing the fatty acid acyl and sphingosyl structures of visceral and CNS glucosylceramides from affected patients, Svennerholm's group demonstrated a peripheral source of some CNS glucosylceramides and, presumably, the derived glucosylsphingosines in types 2 and 3 Gaucher disease (29) . If centrally stored toxic compounds could equilibrate across the blood-brain banier, nonpermanent CNS effects of Gaucher disease might be improved or stabilized after depletion of the peripheral pool of glucosylceramide(s). Such a mechanism may be required for efficacy of enzyme replacement therapy, because exogenously administered enzyme was not found in brain tissue of a patient who had received mannoseterminated acid P-glucosidase (1 3). Similarly, the acid P-glucosidase levels in brain from the present patient were in the range obtained for Gaucher dsease patients ( Table 4) . As a result, efficacy of BMT in neuronopathic Gaucher disease also may require an equilibration or redistribution mechanism.
The clinical course, early developmental delay, and requirement for early splenectomy in the present patient were similar to those in Norrbottnian type 3 patients classified as severe by Dreborg et al. (30) . Similar to our patient, these untransplanted patients had severe growth delay and required splenectomy shortly after diagnosis. Many of these Norrbottnian patients had progressive neurologic deterioration with a loss of about 30 to 50 intelligence quotient points from ages 5 to 15 y. Unfortunately, data from earlier time points were not available in that study. Our patient appeared to be following a similar but earlier pattern, and we would have expected progressive deterioration during the 24 mo of posttransplantation follow-up. No new hard neurologic signs developed in our patient after transplantation, but these are variable in the Norrbottnian patients (30) . Because our patient's psychomotor development remained constant, albeit lower than normal, for the 2 y after transplantation and no significant increase in brain enzyme level was found at autopsy, some mechanism, i.e. equilibration out of the CNS, would have to be invoked to account for her maintanence of her developmental status and prevention of further deterioration. This result was similar to that observed in two Norrbottnian type 3 patients who received BMT at about 2-3 y of age (9) . However, there may be a critical threshold for CNS efficacy of BMT, inasmuch as a 9-y-old Norrbottnian type 3 patient continued slow psychomotor deterioration after successful transplantation (3 1). Clearly, the demonstrated efficacy of enzyme replacement therapy (10-13) and BMT for Gaucher disease provide the rationale for gene therapy strategies via organoid or stem cell replacement approaches for the control and potential cure of Gaucher disease.
